OncoMatch/Breast Cancer/PIK3CA
Breast CancerPIK3CA Clinical Trials
PIK3CA activating mutations occur in approximately 40% of HR+/HER2-negative breast cancers and predict benefit from alpelisib, an alpha-specific PI3K inhibitor approved with fulvestrant for metastatic PIK3CA-mutant disease. PIK3CA mutations are associated with endocrine resistance mechanisms. Trials explore next-generation PI3K/AKT/mTOR inhibitors, AKT inhibitor combinations (capivasertib), and biomarker selection strategies.
Top recruiting PIK3CA Breast Cancer trials
Ranked by phase and US site count. See all 25 trials matched to your profile →
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Eli Lilly and Company
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
Pfizer
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
Relay Therapeutics, Inc.
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
Hoffmann-La Roche
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
Celcuity Inc
A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
Hoffmann-La Roche
Browse other molecular targets with active Breast Cancer trials.